What PRN medication is appropriate for treating intermittent anxiety in an adult patient with multiple sclerosis?

PRN Medication for Anxiety in Multiple Sclerosis

For intermittent anxiety in an adult patient with multiple sclerosis, lorazepam 0.5-1 mg orally as needed (maximum 4 mg in 24 hours) is the recommended PRN medication, with dose reduction to 0.25-0.5 mg in elderly or debilitated patients (maximum 2 mg in 24 hours). 1

Rationale and Dosing

The NICE guidelines specifically recommend lorazepam for PRN management of anxiety in adults who are able to swallow 1. This benzodiazepine is preferred for PRN use because:

• Short half-life minimizes accumulation with intermittent dosing
• Oral tablets can be used sublingually (off-label) for faster onset if needed 1
• Well-established dosing parameters with clear maximum daily limits

Critical Safety Considerations

Benzodiazepines carry significant risks that must be weighed carefully:

• Regular use leads to tolerance, addiction, depression, and cognitive impairment 2
• Paradoxical agitation occurs in approximately 10% of patients 2
• Infrequent, low doses are least problematic 2
• In MS patients specifically, cognitive impairment from benzodiazepines may compound existing MS-related cognitive symptoms

Alternative Approach for Chronic Anxiety

If anxiety is more than intermittent, SSRIs (fluvoxamine, paroxetine, escitalopram, sertraline) should be considered as first-line daily therapy rather than PRN benzodiazepines 3. SSRIs have:

• High treatment response rates (NNT = 4.70) 3
• Similar dropout rates to placebo, indicating good tolerability 3
• No risk of dependence or cognitive impairment associated with chronic benzodiazepine use

Clinical Algorithm

For truly intermittent anxiety (occasional episodes):

• Start lorazepam 0.5 mg PRN
• Maximum 4 doses per 24 hours
• If needed more than twice weekly, reassess for daily SSRI therapy

For elderly or debilitated MS patients:

• Start lorazepam 0.25 mg PRN
• Maximum 2 mg total in 24 hours
• Monitor closely for paradoxical reactions and cognitive effects

If unable to swallow (rare in MS unless severe dysphagia):

• Midazolam 2.5-5 mg subcutaneously every 2-4 hours as required 1

Important Caveats

The evidence provided does not specifically address MS patients, but the general anxiety management principles apply. MS patients may have additional considerations including:

• Drug interactions with disease-modifying therapies (check specific MS medications)
• Increased fall risk from both MS-related mobility issues and benzodiazepine-induced sedation
• Cognitive effects may be more pronounced in MS patients with existing cognitive impairment

Non-pharmacological interventions should be attempted first when clinically appropriate, including exploring patient concerns, ensuring effective communication, and addressing reversible causes of anxiety 1. However, when PRN medication is indicated for acute symptom relief, lorazepam remains the evidence-based choice.